First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial

Saved in:

Bibliographic Details
Main Authors:	Yelena Y. Janjigian, Steven B. Maron, Walid K. Chatila, Brittanie M Millang, Shweta S. Chavan, Carly Alterman, Joanne F. Chou, Michal Segal, Marc Simmons, Parisa Momtaz, Marina Shcherba, Geoffrey Y. Ku, Alice Zervoudakis, Elizabeth Won, David P. Kelsen, David H. Ilson, Rebecca J. Nagy, Richard B. Lanman, Ryan Ptashkin, Mark T.A. Donoghue, Marinela Capanu, Barry S. Taylor, David B. Solit, Nikolaus Schultz, Jaclyn F. Hechtman
Format:	Artigo
Language:	English
Published:	2020
Online Access:	https://doi.org/10.1016/s1470-2045(20)30169-8 https://www.sciencedirect.com/science/article/am/pii/S1470204520301698
Tags:	Add Tag No Tags, Be the first to tag this record!

Internet